Yunnan Baiyao Group Co., Ltd is a Chinese pharmaceutical company that develops and manufactures pharmaceutical products (mainly traditional Chinese medicine) and the wholesale and retail of pharmaceutical products.[2]
The Government Pension Fund of Norway has excluded the company from investments since 21 December 2021, since the company "uses and sells body parts from pangolins which is a globally endangered species".[3]
As of 2024, state and individual investors hold 29% of the shares and private companies hold 35%. The three largest shareholders hold 58 per cent of the company's shares.[4]
Corporate affairs
As of December 31, 2007, the company had 12 subsidiaries, engaged in the pharmaceutical industry, and four major associates, involved in securities, investment and biotechnological research.